Skip to main content
Top
Published in: Cancer Imaging 1/2019

Open Access 01-12-2019 | Uterine Sarcoma | Research article

Investigating the diagnostic value of quantitative parameters based on T2-weighted and contrast-enhanced MRI with psoas muscle and outer myometrium as internal references for differentiating uterine sarcomas from leiomyomas at 3T MRI

Authors: Mahrooz Malek, Maryam Rahmani, Seyyedeh Mahdieh Seyyed Ebrahimi, Elnaz Tabibian, Azadeh Alidoosti, Pariya Rahimifar, Setareh Akhavan, Ziba Gandomkar

Published in: Cancer Imaging | Issue 1/2019

Login to get access

Abstract

Background

Post-hysterectomy histopathological examination is currently the main diagnostic tool for differentiating uterine sarcomas from leiomyomas. This study aimed to investigate the diagnostic accuracy of preoperative quantitative metrics based on T2-weighted sequences and contrast-enhanced MRI (CE-MRI) for distinguishing uterine sarcomas from leiomyomas.

Materials and methods

The institutional review board approved the study. Sixty-five women confirmed to have a total of 105 lesions participated. Routine pelvic MRI sequences, T2 map and CE-MRI images were performed preoperatively using a 3 T MR scanner. Six quantitative metrics—T2 mapping parameter, T2 scaled ratio, tumor myometrium contrast ratio on T2, tumor psoas contrast ratio on T2, tumor myometrium contrast-enhanced ratio, and tumor psoas contrast-enhanced ratio—were extracted from the acquired image sets. Chi-square test was used to compare the percentage of malignant lesions with the central necrosis to the corresponding percentage for the benign masses. Using the area under receiver operating characteristic (AUC) curve, the performance of different metrics for distinguishing uterine sarcomas from leiomyomas was measured. Moreover, for each metric, we extracted the optimal cut-off value. The values of sensitivity, specificity, negative predictive value, and positive predictive value were calculted for the classifiers based on different metrics.

Results

The average age, average lesion size, and proportion of premenopausal women in benign and malignant groups were comparable in our dataset. The signal intensity of uterine sarcomas at T2-weighted sequences was significantly higher than that of leiomyomas (p < 0.001), while intensity at T1-weighted sequences exhibited no significant difference between the two masses (p = 0.201). Our data also suggested that a central necrosis was ten times more common among malignant lesions compared to benign ones (p < 0.001). Among different metrics, T2 mapping parameter achieved the highest AUC value and accuracy in differentiating two groups. Three measures—T2 scaled ratio, tumor myometrium contrast ratio on T2, and tumor myometrium contrast-enhanced ratio—achieved a sensitivity of 100%, therefore none of the malignant lesions would have been missed if these metrics had been adopted in patient management.

Conclusions

The findings suggested that the evaluated metrics could be useful in the preoperative assessment of myometrial masses to differentiate uterine sarcomas from leiomyomas. The proposed framework has major implications for improving current practice in the management of myometrial masses.
Literature
1.
go back to reference D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116:131–9.CrossRef D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116:131–9.CrossRef
2.
go back to reference Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Women's Health. 2014;6:95.CrossRef Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Women's Health. 2014;6:95.CrossRef
3.
go back to reference Stewart EA, Barbieri RL, Goff B, Falcone T, Falk SJ. Differentiating uterine leiomyomas (fibroids) from uterine sarcomas. Waltham: UpToDate; 2015. Accessed on 10 November 2015 Stewart EA, Barbieri RL, Goff B, Falcone T, Falk SJ. Differentiating uterine leiomyomas (fibroids) from uterine sarcomas. Waltham: UpToDate; 2015. Accessed on 10 November 2015
4.
go back to reference Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6–6.CrossRef Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6–6.CrossRef
5.
go back to reference Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Women's Health. 2014;6:95–114.CrossRef Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Women's Health. 2014;6:95–114.CrossRef
6.
go back to reference Smith SJ. Uterine fibroid embolization. Am Fam Physician. 2000;61:3601–14.PubMed Smith SJ. Uterine fibroid embolization. Am Fam Physician. 2000;61:3601–14.PubMed
7.
go back to reference Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol. 1993;24:1073–7.CrossRef Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol. 1993;24:1073–7.CrossRef
8.
go back to reference Leibsohn S, d'Ablaing G, Mishell DR, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162:968–76.CrossRef Leibsohn S, d'Ablaing G, Mishell DR, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162:968–76.CrossRef
9.
go back to reference Bansal N, Herzog TJ, Burke W, Cohen CJ, Wright JD. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol. 2008;110:43–8.CrossRef Bansal N, Herzog TJ, Burke W, Cohen CJ, Wright JD. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol. 2008;110:43–8.CrossRef
10.
go back to reference Morice P, Rodriguez A, Rey A, Pautier P, Atallah D, Genestie C, Pomel C, Lhommé C, Haie-Meder C, Duvillard P. Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol. 2003;24:237–40.PubMed Morice P, Rodriguez A, Rey A, Pautier P, Atallah D, Genestie C, Pomel C, Lhommé C, Haie-Meder C, Duvillard P. Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol. 2003;24:237–40.PubMed
11.
go back to reference Perri T, Korach J, Sadetzki S, Oberman B, Fridman E, Ben-Baruch G. Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer. 2009;19:257–60.CrossRef Perri T, Korach J, Sadetzki S, Oberman B, Fridman E, Ben-Baruch G. Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer. 2009;19:257–60.CrossRef
12.
go back to reference George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014;120:3154–8.CrossRef George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014;120:3154–8.CrossRef
13.
go back to reference Carta G, Palermo P, Di Ramio R, De Lellis V, Carta A, Patacchiola F. Leiomyosarcoma after hysteroscopic myomectomy: a case report. Eur J Gynaecol Oncol. 2012;33:656–7.PubMed Carta G, Palermo P, Di Ramio R, De Lellis V, Carta A, Patacchiola F. Leiomyosarcoma after hysteroscopic myomectomy: a case report. Eur J Gynaecol Oncol. 2012;33:656–7.PubMed
14.
go back to reference Sahdev A, Sohaib S, Jacobs I, Shepherd J, Oram D, Reznek R. MR imaging of uterine sarcomas. Am J Roentgenol. 2001;177:1307–11.CrossRef Sahdev A, Sohaib S, Jacobs I, Shepherd J, Oram D, Reznek R. MR imaging of uterine sarcomas. Am J Roentgenol. 2001;177:1307–11.CrossRef
15.
go back to reference Hricak H, Finck S, Honda G, Goranson H. MR imaging in the evaluation of benign uterine masses: value of gadopentetate dimeglumine-enhanced T1-weighted images. AJR Am J Roentgenol. 1992;158:1043–50.CrossRef Hricak H, Finck S, Honda G, Goranson H. MR imaging in the evaluation of benign uterine masses: value of gadopentetate dimeglumine-enhanced T1-weighted images. AJR Am J Roentgenol. 1992;158:1043–50.CrossRef
16.
go back to reference Murase E, Siegelman ES, Outwater EK, Perez-Jaffe LA, Tureck RW. Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics. 1999;19:1179–97.CrossRef Murase E, Siegelman ES, Outwater EK, Perez-Jaffe LA, Tureck RW. Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics. 1999;19:1179–97.CrossRef
17.
go back to reference Ueda H, Togashi K, Konishi I, Kataoka ML, Koyama T, Fujiwara T, Kobayashi H, Fujii S, Konishi J. Unusual appearances of uterine leiomyomas: MR imaging findings and their histopathologic backgrounds. Radiographics. 1999;19:S131–45.CrossRef Ueda H, Togashi K, Konishi I, Kataoka ML, Koyama T, Fujiwara T, Kobayashi H, Fujii S, Konishi J. Unusual appearances of uterine leiomyomas: MR imaging findings and their histopathologic backgrounds. Radiographics. 1999;19:S131–45.CrossRef
18.
go back to reference Schwartz LB, Zawin M, Carcangiu ML, Lange R, McCarthy S. Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertil Steril. 1998;70:580–7.CrossRef Schwartz LB, Zawin M, Carcangiu ML, Lange R, McCarthy S. Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertil Steril. 1998;70:580–7.CrossRef
19.
go back to reference Thomassin-Naggara I, Dechoux S, Bonneau C, Morel A, Rouzier R, Carette M-F, Daraï E, Bazot M. How to differentiate benign from malignant myometrial tumours using MR imaging. Eur Radiol. 2013;23:2306–14.CrossRef Thomassin-Naggara I, Dechoux S, Bonneau C, Morel A, Rouzier R, Carette M-F, Daraï E, Bazot M. How to differentiate benign from malignant myometrial tumours using MR imaging. Eur Radiol. 2013;23:2306–14.CrossRef
20.
go back to reference Sato K, Yuasa N, Fujita M, Fukushima Y. Clinical application of diffusion-weighted imaging for preoperative differentiation between uterine leiomyoma and leiomyosarcoma. Am J Obstet Gynecol. 2014;210:368 e361–368. e368.CrossRef Sato K, Yuasa N, Fujita M, Fukushima Y. Clinical application of diffusion-weighted imaging for preoperative differentiation between uterine leiomyoma and leiomyosarcoma. Am J Obstet Gynecol. 2014;210:368 e361–368. e368.CrossRef
21.
go back to reference Parker WH, Kaunitz AM, Pritts EA, Olive DL, Chalas E, Clarke-Pearson DL, Berek JS. US Food and Drug Administration's guidance regarding morcellation of leiomyomas: well-intentioned, but is it harmful for women? Obstet Gynecol. 2016;127:18–22.CrossRef Parker WH, Kaunitz AM, Pritts EA, Olive DL, Chalas E, Clarke-Pearson DL, Berek JS. US Food and Drug Administration's guidance regarding morcellation of leiomyomas: well-intentioned, but is it harmful for women? Obstet Gynecol. 2016;127:18–22.CrossRef
22.
go back to reference Namimoto T, Yamashita Y, Awai K, Nakaura T, Yanaga Y, Hirai T, Saito T, Katabuchi H. Combined use of T2-weighted and diffusion-weighted 3-T MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol. 2009;19:2756.CrossRef Namimoto T, Yamashita Y, Awai K, Nakaura T, Yanaga Y, Hirai T, Saito T, Katabuchi H. Combined use of T2-weighted and diffusion-weighted 3-T MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol. 2009;19:2756.CrossRef
23.
go back to reference Carter JS, Koopmeiners JS, Kuehn-Hajder JE, Metzger GJ, Lakkadi N, Downs LS, Bolan PJ. Quantitative multiparametric MRI of ovarian cancer. J Magn Reson Imaging. 2013;38:1501–9.CrossRef Carter JS, Koopmeiners JS, Kuehn-Hajder JE, Metzger GJ, Lakkadi N, Downs LS, Bolan PJ. Quantitative multiparametric MRI of ovarian cancer. J Magn Reson Imaging. 2013;38:1501–9.CrossRef
24.
go back to reference Liu L, Yin B, Geng DY, Lu YP, Peng WJ. Changes of T2 relaxation time from neoadjuvant chemotherapy in breast Cancer lesions. Iran J Radiol. 2016;13:e24014.PubMedPubMedCentral Liu L, Yin B, Geng DY, Lu YP, Peng WJ. Changes of T2 relaxation time from neoadjuvant chemotherapy in breast Cancer lesions. Iran J Radiol. 2016;13:e24014.PubMedPubMedCentral
25.
go back to reference Kang SH, Lee SJ, Jeon GS, Yoon S-W. Scaled signal intensity of uterine fibroids on T2-weighted MR imaging as a predictor of the potential response to uterine fibroid embolization. J Vasc Interv Radiol. 2017;28:844–9.CrossRef Kang SH, Lee SJ, Jeon GS, Yoon S-W. Scaled signal intensity of uterine fibroids on T2-weighted MR imaging as a predictor of the potential response to uterine fibroid embolization. J Vasc Interv Radiol. 2017;28:844–9.CrossRef
26.
go back to reference SUMI A, TERASAKI H, SANADA S, UCHIDA M, TOMIOKA Y, KAMURA T, YANO H, ABE T. Assessment of MR imaging as a tool to differentiate between the major histological types of uterine sarcomas. Magn Reson Med Sci. 2015;14:295–304.CrossRef SUMI A, TERASAKI H, SANADA S, UCHIDA M, TOMIOKA Y, KAMURA T, YANO H, ABE T. Assessment of MR imaging as a tool to differentiate between the major histological types of uterine sarcomas. Magn Reson Med Sci. 2015;14:295–304.CrossRef
27.
go back to reference Haynor DR, Mack LA, Soules MR, Shuman W, Montana M, Moss A. Changing appearance of the normal uterus during the menstrual cycle: MR studies. Radiology. 1986;161:459–62.CrossRef Haynor DR, Mack LA, Soules MR, Shuman W, Montana M, Moss A. Changing appearance of the normal uterus during the menstrual cycle: MR studies. Radiology. 1986;161:459–62.CrossRef
28.
go back to reference Seki H, Kimura M, Sakai K. Myometrial invasion of endometrial carcinoma: Assessment with dynamic MR and contrast-enhanced T1-weighted images. Clin Radiol. 1997;52:18–23.CrossRef Seki H, Kimura M, Sakai K. Myometrial invasion of endometrial carcinoma: Assessment with dynamic MR and contrast-enhanced T1-weighted images. Clin Radiol. 1997;52:18–23.CrossRef
29.
go back to reference McHugh ML. Interrater reliability: the kappa statistic. Biochemia medica: Biochemia medica. 2012;22:276–82.CrossRef McHugh ML. Interrater reliability: the kappa statistic. Biochemia medica: Biochemia medica. 2012;22:276–82.CrossRef
30.
go back to reference Hricak H, Tscholakoff D, Heinrichs L, Fisher M, Dooms G, Reinhold C, Jaffe R. Uterine leiomyomas: correlation of MR, histopathologic findings, and symptoms. Radiology. 1986;158:385–91.CrossRef Hricak H, Tscholakoff D, Heinrichs L, Fisher M, Dooms G, Reinhold C, Jaffe R. Uterine leiomyomas: correlation of MR, histopathologic findings, and symptoms. Radiology. 1986;158:385–91.CrossRef
31.
go back to reference Togashi K, Ozasa H, Konishi I, Itoh H, Nishimura K, Fujisawa I, Noma S, Sagoh T, Minami S, Yamashita K. Enlarged uterus: differentiation between adenomyosis and leiomyoma with MR imaging. Radiology. 1989;171:531–4.CrossRef Togashi K, Ozasa H, Konishi I, Itoh H, Nishimura K, Fujisawa I, Noma S, Sagoh T, Minami S, Yamashita K. Enlarged uterus: differentiation between adenomyosis and leiomyoma with MR imaging. Radiology. 1989;171:531–4.CrossRef
32.
go back to reference Okizuka H, Sugimura K, Takemori M, Obayashi C, Kitao M, Ishida T. MR detection of degenerating uterine leiomyomas. J Comput Assist Tomogr. 1993;17:760–6.CrossRef Okizuka H, Sugimura K, Takemori M, Obayashi C, Kitao M, Ishida T. MR detection of degenerating uterine leiomyomas. J Comput Assist Tomogr. 1993;17:760–6.CrossRef
33.
go back to reference Hoang Dinh A, Souchon R, Melodelima C, Bratan F, Mège-Lechevallier F, Colombel M, Rouvière O. Characterization of prostate cancer using T2 mapping at 3T: a multi-scanner study. Diagn Interv Imaging. 2015;96:365–72.CrossRef Hoang Dinh A, Souchon R, Melodelima C, Bratan F, Mège-Lechevallier F, Colombel M, Rouvière O. Characterization of prostate cancer using T2 mapping at 3T: a multi-scanner study. Diagn Interv Imaging. 2015;96:365–72.CrossRef
34.
go back to reference Lin G, Yang LY, Huang YT, Ng KK, Ng SH, Ueng SH, Chao A, Yen TC, Chang TC, Lai CH. Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma/smooth muscle tumor with uncertain malignant potential and benign leiomyoma. J Magn Reson Imaging. 2016;43:333–42.CrossRef Lin G, Yang LY, Huang YT, Ng KK, Ng SH, Ueng SH, Chao A, Yen TC, Chang TC, Lai CH. Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma/smooth muscle tumor with uncertain malignant potential and benign leiomyoma. J Magn Reson Imaging. 2016;43:333–42.CrossRef
35.
go back to reference Malek M, Gity M, Alidoosti A, Oghabian Z, Rahimifar P, Ebrahimi SMS, Tabibian E, Oghabian MA. A machine learning approach for distinguishing uterine sarcoma from leiomyomas based on perfusion weighted MRI parameters. Eur J Radiol. 2019;110:203–11.CrossRef Malek M, Gity M, Alidoosti A, Oghabian Z, Rahimifar P, Ebrahimi SMS, Tabibian E, Oghabian MA. A machine learning approach for distinguishing uterine sarcoma from leiomyomas based on perfusion weighted MRI parameters. Eur J Radiol. 2019;110:203–11.CrossRef
Metadata
Title
Investigating the diagnostic value of quantitative parameters based on T2-weighted and contrast-enhanced MRI with psoas muscle and outer myometrium as internal references for differentiating uterine sarcomas from leiomyomas at 3T MRI
Authors
Mahrooz Malek
Maryam Rahmani
Seyyedeh Mahdieh Seyyed Ebrahimi
Elnaz Tabibian
Azadeh Alidoosti
Pariya Rahimifar
Setareh Akhavan
Ziba Gandomkar
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2019
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-019-0206-8

Other articles of this Issue 1/2019

Cancer Imaging 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine